Publications
These are publications from work undertaken by Frontier Science (Scotland).
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial
JAMA Oncol, Pages 227-234, 3(2) doi:10.1001/jamaoncol.2016.3824,
Data Management and Coordination
Wiley StatsRef: Statistics Reference online, 1-14 doi:10.1002/9781118445112.stat04933.pub2,
Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis from the ALTTO Trial
Journal of the National Cancer Institute, Volume 109, Issue 8, doi: 10.1093/jnci/djw331,
Pathway level alterations rather than mutations in single genes predict response to HER2 targeted therapies in the neo-ALTTO trial
Annals of Oncology, Volume 28, Issue 1, p128-135, doi:10.1093/annonc/mdw434,
11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
www.thelancet.com, Volume 389, Issue 10075, pp. 1195-1205, doi:10.1016/S0140-6736(16)32616-2,
Breast ultrasound and mammography and response to neoadjuvant lapatinib, trastuzumab and their combination in HER2 positive breast cancer: Results from Neo-ALTTO (BIG 1-06)
Cancer Research, Volume 76, Issue 4, doi:10.1158/1538-7445.SABCS15-P6-01-04,
The impact of registration of clinical trials units: the UK experience
Clinical Trials, Volume 12, Issue 2, Pages 166-173, doi:10.1177/1740774514561242 ,
Trastuzumab Re-Treatment Following Adjuvant Trastuzumab and the Importance of Distant Disease-Free Interval: the HERA Trial Experience
Breast Cancer Research and Treatment, Volume 155, Issue 1, Pages 127-132,doi: 10.1007%2Fs10549-015-3656-0,
2 Years Versus 1 Year of Adjuvant Trastuzumab for HER2-Positive Breast Cancer (HERA): an Open-Label, Randomised Controlled Trial
The Lancet, Volume 382, Issue 9897, Pages 1021-1028, doi: 10.1016/S0140-6736(13)61094-6,
Magnitude of Trastuzumab benefit in patients with HER2 positive, invasive lobular breast carcinoma: results from the HERA trial
Journal of Clinical Oncology, Volume 31, Issue 16, Pages 1954-1960, doi: 10.1200/JCO.2012.46.2440,